Caribou Biosciences Announces Strategic Review Amid Downgrades
Shares of Caribou Biosciences (CRBU) fell to an all-time low after the biotech firm announced it would explore strategic alternatives. The move prompted downgrades from RBC Capital Markets and Leerink Partners, signaling concerns over its future direction. Caribou is based in Berkeley, California, and focuses on cell therapy development. Its decision to seek strategic options has raised uncertainty among investors about potential changes such as a merger or acquisition. Analysts are now more cautious regarding the company's prospects due to this shift in strategy.
Tickers: $CRBU
Topics: biotech downgrade stock price movement strategic alternatives